---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-173043"
form_type: "8-K"
ticker: "SNSE"
cik: "0001829802"
company_name: "Sensei Biotherapeutics, Inc."
filed_at: "2025-08-05T23:59:59+00:00"
generated_at: "2026-05-17T20:58:48.096135+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Sensei Biotherapeutics Q2 net loss $4.9M; cash runway into Q2 2026; Phase 1/2 data year-end

## Summary
- Cash, cash equivalents and marketable securities $28.6M at June 30, 2025 (down from $41.3M at Dec 31, 2024).
- Net loss $4.9M for Q2 2025 vs $7.1M for Q2 2024; R&D expenses decreased to $2.5M from $4.6M.
- Phase 1/2 dose expansion cohort enrollment complete (64 patients); full data including 6-month PFS expected by year-end 2025.
- Data to be presented at ESMO Congress 2025 (Oct 17-21) in a mini oral session.
- Regained Nasdaq compliance after 1-for-20 reverse split effective June 16, 2025.

## SEC filing metadata
- accession: 0001193125-25-173043
- form_type: 8-K
- ticker: SNSE
- cik: 0001829802
- company_name: Sensei Biotherapeutics, Inc.
- filed_at: 2025-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829802/000119312525173043/0001193125-25-173043-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829802/000119312525173043/d46736d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-173043
- JSON: https://secwatch.observer/filing/0001193125-25-173043.json
- Plain text: https://secwatch.observer/filing/0001193125-25-173043.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.